Pimavanserin Aids Alzheimer’s Patients with Severe Psychosis, Acadia Reports

Pimavanserin Aids Alzheimer’s Patients with Severe Psychosis, Acadia Reports
Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, which stems from additional analyses of data gathered in a Phase 2 trial of pimavanserin in Alzheimer’s patients, was presented at the recent 10th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Boston. While the company announced in December 2016 that the study met its primary goal of reducing psychotic symptoms in Alzheimer’s patients, the presentation covered a subgroup analysis and additional assessments of exploratory outcome measures. Pimavanserin is approved to treat psychosis in Parkinson’s disease patients under the brand name Nuplazid. “In the Phase II -019 Study, pimavanserin significantly reduced psychosis in patients with Alzheimer’s disease without negatively impacting cognition,” Clive Ballard, executive dean of the University of Exeter Medical School, who presented the data at the meeting, said in a press release. The study, which the company refers to as -019, showed that the therapy reduced psychosis compared to placebo after six weeks of treatment. At six weeks, 55.2 percent of pimavanserin-treated patients had improved by at least 30 percent, compared to only 37.4
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *